Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2017. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares via dividend re-investment |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.1348 |
| Volume | 376 shares |
| Transaction Date | July 17, 2017 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of 376 shares by Dr. S. Dexter, a PCA of Dr. P. J. T. Vallance (President, R&D), following the re-investment of dividends paid on July 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory notification of a specific share acquisition event.
Key Facts for Investor Verification
- The transaction was an acquisition of 376 ordinary shares at £16.1348 per share.
- The buyer was Dr. S. Dexter, identified as a PCA of Dr. P. J. T. Vallance.
- The shares were acquired through the re-investment of dividends paid on July 13, 2017.
- The transaction occurred on the London Stock Exchange on July 17, 2017.
- This filing does not contain financial results or strategic updates for the company.